NIAID Virology Quality Assurance
ID: 75N93024R00030Type: Presolicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH NIAIDBETHESDA, MD, 20892, USA

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)

PSC

HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH (AN12)

Original Source

https://sam.gov/opp/959e1c84e77b466dba3fa78196082664/view
Timeline
    Description

    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), is seeking proposals for a comprehensive quality assurance program for virologic assays related to HIV and other viral pathogens. The objective is to ensure the validity and comparability of laboratory data through proficiency testing panels and real-time assay controls, which are critical for ongoing and future studies on infectious diseases. This program has been operational since 1988 and supports approximately 110 laboratories globally, emphasizing the importance of maintaining high standards in virologic testing. Proposals are expected to be submitted electronically via the NIAID electronic Contract Proposal Submission (eCPS) website, with the solicitation anticipated to be available on or about January 9, 2025. For further inquiries, interested parties can contact Shawnice Williams at shawnice.williams@nih.gov or Ashley Kinderdine at ashley.kinderdine@nih.gov.

    Point(s) of Contact
    Shawnice Williams
    (301) 761-5431
    shawnice.williams@nih.gov
    Ashley Kinderdine
    (240) 669-5154
    ashley.kinderdine@nih.gov
    Files
    No associated files provided.
    Lifecycle
    Title
    Type
    NIAID Virology Quality Assurance
    Currently viewing
    Presolicitation
    NIAID Virology Quality Assurance
    Sources Sought
    Similar Opportunities
    In Vitro Assessments of Antimicrobial Activity
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), is seeking proposals for the In Vitro Assessments of Antimicrobial Activity program to support in vitro testing for evaluating the therapeutic potential of compounds against infectious diseases. This initiative aims to enhance the understanding and treatment of infectious diseases by providing efficient assessment tools integrated into the product development pipeline, focusing on various pathogens including bacteria, fungi, viruses, and challenging pathogens that require innovative culturing techniques. The RFP will be available online around December 30, 2024, and proposals must be submitted via the NIAID electronic Contract Proposal Submission (eCPS) platform; interested parties can contact Alexander Beraud at alexander.beraud@nih.gov or Brian Madgey at brian.madgey@nih.gov for further information.
    NIAID CLINICAL PRODUCTS CENTER (CPC)
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), is seeking proposals for a contract to provide pharmacy and pharmaceutical oversight for clinical trials, both nationally and internationally. The primary objective of this contract is to ensure the integrity of study products, participant safety, and compliance with pharmacy and pharmaceutical regulations throughout various NIH-funded clinical trials. This opportunity is critical for maintaining high standards in public health research, as it encompasses a wide range of services including product management, regulatory document maintenance, and clinical laboratory testing. Proposals are due by January 17, 2025, with the contract expected to commence on April 1, 2026, and run through March 31, 2027, potentially extending through 2033. Interested parties can contact Deborah Blyveis at blyveisd@niaid.nih.gov or Emily Bannister at emily.bannister@nih.gov for further information.
    Single-plex NULISApcr Absolute Quantification Assay of HDGFL2 in Plasma Samples
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is soliciting proposals for the development of a single-plex NULISApcr absolute quantification assay to measure HDGFL2 levels in plasma samples, linked to TDP-43 dysfunction associated with Alzheimer’s Disease and Related Dementias (ADRD). The project aims to establish a biomarker for HDGFL2, which is crucial for advancing research and treatment in neurological disorders. The anticipated contract will be a firm fixed-price purchase order with a performance period of twelve months, and proposals must be submitted electronically to Emily Palombo at emily.palombo@nih.gov by 9:00 a.m. Eastern Daylight Time on December 23, 2024. Interested parties should ensure compliance with all relevant FAR provisions and include necessary certifications in their submissions.
    Assay Kits for Lumipulse instrument
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking proposals for the procurement of assay kits for the Lumipulse instrument, aimed at quantifying specific biomarkers related to Alzheimer's Disease. The acquisition includes a total of 4,410 assays for biomarkers abeta42, abeta40, and pTau 217, which will be utilized in research involving stored samples from the Baltimore Longitudinal Study of Aging (BLSA) to assess cognitive decline and neurodegeneration. This procurement is critical for advancing Alzheimer’s research and will be awarded as a firm fixed-price purchase order, with quotations due by 5:00 p.m. Eastern Time on January 8, 2025. Interested vendors should contact Iris Merscher at iris.merscher@nih.gov for further details.
    2026 NIAID DMID Omnibus Broad Agency Announcement
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and specifically the National Institute of Allergy and Infectious Diseases (NIAID), is soliciting proposals for the 2026 DMID Omnibus Broad Agency Announcement (BAA) aimed at advancing research and development of medical countermeasures against antimicrobial-resistant pathogens and viruses with pandemic potential. The BAA encompasses two primary research areas: the development of therapeutics, vaccines, and diagnostics for antimicrobial-resistant bacterial and fungal pathogens, and the creation of direct-acting antivirals for viral families of pandemic potential. This initiative is critical for addressing public health challenges related to infectious diseases and enhancing biodefense capabilities. Proposals for Research Area 001 are due by February 21, 2025, while those for Research Area 002 are due by January 21, 2025. Interested parties can reach out to primary contact Swee L. Teo at teosl@niaid.nih.gov or 240-669-5173 for further information.
    National Institute of Environmental Health Sciences (NIEHS) Assessment of Immunotoxicity – In Vitro and In Vivo Assessment of Immune Function
    Active
    Health And Human Services, Department Of
    The National Institute of Environmental Health Sciences (NIEHS), part of the Department of Health and Human Services, is seeking proposals for a federal contract focused on the assessment of immunotoxicity through in vitro and in vivo evaluation of immune function. The objective is to provide comprehensive research services to evaluate how selected test agents may modulate immune responses, utilizing both established and innovative methodologies to reduce animal use in toxicology studies. This contract, anticipated to be a cost-plus-fixed-fee type, is expected to be awarded by September 2025, with a base period of one year and nine optional one-year extensions. Interested parties should direct inquiries to Adam Muhsin at adam.muhsin@nih.gov and monitor the Sam.gov website for the solicitation release, which is expected no sooner than 15 days from this notice.
    cDNA-PCR Sequencing Kits for long-read sequencing.
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking proposals for the procurement of cDNA-PCR Sequencing Kits for long-read sequencing, as part of a combined synopsis/solicitation. The primary objective is to acquire Promethion Flow Cell packs and sequencing kits to support high-throughput sequencing efforts aimed at advancing research on neurodegenerative diseases, particularly Alzheimer's disease. This procurement is crucial for the Center for Alzheimer’s Disease and Related Dementias (CARD) and is expected to facilitate the identification of causative genes and potential therapeutic targets. Interested vendors must submit their quotations by 5:00 p.m. Eastern Time on December 30, 2024, referencing Solicitation Number 75N95025Q00008, and can direct inquiries to Iris Merscher at iris.merscher@nih.gov or by phone at 301-827-2547.
    NCI OA Special Notice of Subcontract Opportunity at the Frederick National Laboratory for Cancer Research
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Cancer Institute (NCI), has issued a Special Notice regarding a subcontract opportunity at the Frederick National Laboratory for Cancer Research (FNLCR) aimed at enhancing laboratory practices to meet Good Clinical Laboratory Practice (GCLP) standards. The primary objective is to engage a subcontractor to evaluate current laboratory operations, identify compliance gaps, and implement improvements related to sample management, data integrity, and overall laboratory quality standards. This initiative is crucial for ensuring the integrity of testing and data management, which will facilitate the approval of new vaccine recommendations and enhance the laboratory's quality management system. Interested parties should note that this notice is for informational purposes only, with responses treated as government property, and are encouraged to monitor SAM.gov for updates. The deadline for submissions is January 3, 2025, at noon EST, and inquiries can be directed to Jennifer Gnuschke at jennifer.gnuschke@nih.gov.
    NHANES General Chemistry Laboratory Testing 2025-2030
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), is seeking proposals for the NHANES General Chemistry Laboratory Testing contract, which will span from February 14, 2025, to February 13, 2030. The primary objective of this procurement is to obtain Clinical Laboratory Improvement Amendments (CLIA) certified laboratory measurements on biological specimens collected through the National Health and Nutrition Examination Survey (NHANES), which aims to provide national statistics on the health and nutritional status of the U.S. population. This contract is crucial for generating national estimates and monitoring trends in chronic diseases, with the contractor responsible for conducting a variety of chemistry tests, including a Comprehensive Metabolic Panel and lipid panels, while ensuring strict confidentiality and compliance with ethical standards. Interested offerors must submit their proposals electronically by the specified deadlines, with a focus on demonstrating technical capabilities and relevant past performance, and can contact David Santimaw at zgm2@cdc.gov or 770-488-5282 for further information.
    Synopsis of Proposed Contract Action
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), is seeking proposals for a contract focused on the development and testing of systems for the National Health and Nutrition Examination Survey (NHANES) chemistry data. The primary objectives include performing laboratory testing, specifically for a Comprehensive Metabolic Panel (CMP) and additional biochemical tests, while ensuring compliance with CLIA regulations and submitting results within 21 days of sample receipt. This initiative is crucial for enhancing public health data collection and management, with an estimated annual workload of 3,000 to 5,000 samples. Interested contractors must have active registration in the System for Award Management, and the solicitation is expected to be available on SAM.gov around December 16, 2024. For further inquiries, potential bidders can contact David Santimaw at zgm2@cdc.gov or 770-488-5282, or Arianna Williams at xsm2@cdc.gov or 770-488-5036.